Določanje mutacije V600E v genu BRAF

Določanje mutacije V600E v genu BRAF

Mutacija V600E predstavlja več kot 90 % vseh opisanih mutacij v genu BRAF pri različnih vrstah tumorjev. Protein, ki nastane kot produkt onkogena BRAF z mutacijo V600E (BrafV600E), sproža nenehno signaliziranje prek signalne poti RAS-RAF-MAPK, kar povzroči številnejše delitve celice in njeno maligno...

Full description

Bibliographic Details
Main Authors:	Petra Škerl, Alenka Ličar, Srdjan Novaković
Format:	Article
Language:	Slovenian
Published:	Institute of Oncology Ljubljana 2010-12-01
Series:	Onkologija
Subjects:	mutacije V600E gen BRAF
Online Access:	https://revijaonkologija.si/Onkologija/article/view/287

Similar Items

Določanje mutacij pri bolnikih z dedno obliko malignega melanoma kože
by: Petra Škerl, et al.
Published: (2008-12-01)

Določanje mutacij v genih c-KIT in PDGFRA pri bolnikih z gastrointestinalnimi stromalnimi tumorji
by: Marina Grgić, et al.
Published: (2014-06-01)

Presejanje
by: Alenka Ličar, et al.
Published: (2008-12-01)

Določanje polimorfizmov in mutacij v genih MLH1 in MSH2 pri nepolipoznem raku debelega črevesa
by: Vida Stegel, et al.
Published: (2008-12-01)

Implicaciones diagnósticas, terapéuticas y pronósticas de la mutación BRAF V600E en melanomas cutáneos
by: Alberto José Piamo Morales
Published: (2019-05-01)

Več obrazov sindroma Lynch
by: Uršula Prosenc, et al.
Published: (2013-12-01)

Oncogenic BRAF(V600E) Induces Clastogenesis and UVB Hypersensitivity
by: Dennis A. Simpson, et al.
Published: (2015-06-01)

BRAF V600E MUTATIONS IN METASTATIC MELANOMA - CASE REPORT
by: Ivana Inić, et al.
Published: (2014-09-01)

BRAF non-V600E more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAF V600E but without a survival advantage
by: Wei Wang, et al.
Published: (2021-05-01)

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
by: Alessandro Nepote, et al.
Published: (2022-02-01)

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma
by: Priscilla Denise Zepeda-Lopez, et al.
Published: (2016-04-01)

BRAF Non-V600 Mutations in Metastatic Colorectal Cancer
by: Junjia Liu, et al.
Published: (2023-09-01)

Extended Antitumor Responseof a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
by: Siraj M. Ali, et al.
Published: (2014-05-01)

Clinical research progress in the treatment of BRAF V600 mutation-positive advanced melanoma
by: JIANG Jianyun, YING Hongmei
Published: (2022-05-01)

BRAF V600E Mutation in Malignant Melanoma—A Romanian Research Experience
by: Elena-Roxana Avădănei, et al.
Published: (2024-02-01)

Machine learning-based radiomics for predicting BRAF-V600E mutations in ameloblastoma
by: Wen Li, et al.
Published: (2023-08-01)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
by: Ken Saijo, et al.
Published: (2022-08-01)

BRAF V600E and lymph node metastases in papillary thyroid cancer
by: Pan Chen, et al.
Published: (2020-10-01)

Prevalence of BRAF V600E Mutation in the Iranian Patients with Hairy Cell Leukemia: A Retrospective Study
by: Mojtaba Karimi, et al.
Published: (2021-06-01)

Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review
by: Morena Fasano, et al.
Published: (2022-01-01)

Result Analysis of BRAF V600E Gene Mutation Using Molecular and Immunohistochemistry Detection in Acral Malignant Melanoma
by: Hermin Aminah Usman, et al.
Published: (2018-09-01)

Desmoplastic infantile astrocytoma with atypical phenotype, PTEN homozygous deletion and BRAF V600E mutation
by: Javier Megías, et al.
Published: (2022-06-01)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
by: Matthias Lang, et al.
Published: (2023-03-01)

Enrichment of SOX2-Positive Cells in BRAF V600E Mutated and Recurrent Ameloblastoma
by: Chih-Huang Tseng, et al.
Published: (2022-01-01)

Odkrivanje dednega sindroma von Hippel-Lindau
by: Maša Milatovič, et al.
Published: (2012-12-01)

Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma
by: Changjiao Yan, et al.
Published: (2019-07-01)

Colon metastasis from lung adenocarcinoma with BRAF V600E mutation: A case report
by: Yuhao Luo, et al.
Published: (2022-08-01)

Hairy cell leukemia with CCND1/IGH fusion gene and BRAF V600E mutation
by: Zaid Abdel Rahman, et al.
Published: (2020-01-01)

BRAF V600E potentially determines “Oncological Resectability” for “Technically Resectable” colorectal liver metastases
by: Shin Kobayashi, et al.
Published: (2021-10-01)

The BRAF V600E Mutation Detection by quasa Sensitive Real-Time PCR Assay in Northeast Romania Melanoma Patients
by: Elena Porumb-Andrese, et al.
Published: (2021-10-01)

BRAF V600E-Mutant Glioblastoma with Extracranial Metastases Responsive to Combined BRAF and MEK Targeted Inhibition: A Case Report
by: Vasu Munjapara, et al.
Published: (2022-10-01)

Virtual screening, pharmacokinetic, and DFT studies of anticancer compounds as potential V600E-BRAF kinase inhibitors
by: Abdullahi B. Umar, PhD, et al.
Published: (2023-10-01)

Mutación BRAF V600E en pacientes con cáncer de tiroides. Fundación Clínica Valle del Lili: una serie de casos
by: Guillermo Edinson Guzmán, et al.
Published: (2017-03-01)

Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study
by: Lu Si, et al.
Published: (2018-05-01)

Computational evaluation of potent 2-(1H-imidazol-2-yl) pyridine derivatives as potential V600E-BRAF inhibitors
by: Abdullahi Bello Umar, et al.
Published: (2020-11-01)

New flavone-based arylamides as potential V600E-BRAF inhibitors: Molecular docking, DFT, and pharmacokinetic properties
by: Abdullahi B. Umar, PhD, et al.
Published: (2023-10-01)

Pojav naravnih mutacij pri nekaterih linijah koruze (Zea mays L.) iz genske banke
by: Ludvik ROZMAN, et al.
Published: (2008-05-01)

Association of BRAF V600E immunoexpression with clinicopathological variant groups in papillary thyroid carcinoma
by: Hung Nguyen Van, et al.
Published: (2022-12-01)

In silico evaluation of some 4-(quinolin-2-yl)pyrimidin-2-amine derivatives as potent V600E-BRAF inhibitors with pharmacokinetics ADMET and drug-likeness predictions
by: Abdullahi Bello Umar, et al.
Published: (2020-09-01)

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
by: Eszter Molnár, et al.
Published: (2018-05-01)